Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$20.90
+3.8%
$19.50
$12.21
$41.31
$614.04M-0.2606,543 shs1.71 million shs
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$23.70
-2.2%
$27.79
$22.48
$71.71
$1.40B3.24877,341 shs1.29 million shs
Liquidia Co. stock logo
LQDA
Liquidia
$14.18
-9.1%
$14.76
$8.26
$19.41
$1.21B0.241.08 million shs2.37 million shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$15.84
+0.7%
$14.45
$8.24
$18.38
$1.03B-0.3488,605 shs338,184 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-1.52%-4.60%-2.75%+18.41%-15.81%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-3.89%-4.57%-21.93%-25.64%-46.57%
Liquidia Co. stock logo
LQDA
Liquidia
+1.63%-8.34%+10.48%+0.78%+25.60%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-1.44%-2.30%+17.92%+62.50%+28.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
3.3387 of 5 stars
4.43.00.00.03.11.70.6
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
2.2263 of 5 stars
3.50.00.00.04.13.30.0
Liquidia Co. stock logo
LQDA
Liquidia
3.3783 of 5 stars
4.50.00.00.03.34.20.6
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.7957 of 5 stars
3.51.00.00.03.55.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.70
Moderate Buy$40.3893.18% Upside
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3.09
Buy$95.25301.90% Upside
Liquidia Co. stock logo
LQDA
Liquidia
3.00
Buy$26.6788.06% Upside
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
3.00
Buy$38.00139.90% Upside

Current Analyst Ratings Breakdown

Latest ANAB, LQDA, JANX, and MLYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$54.00 ➝ $90.00
5/28/2025
Liquidia Co. stock logo
LQDA
Liquidia
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$36.00 ➝ $37.00
5/28/2025
Liquidia Co. stock logo
LQDA
Liquidia
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$20.00 ➝ $23.00
5/28/2025
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/28/2025
Liquidia Co. stock logo
LQDA
Liquidia
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$29.00 ➝ $35.00
5/21/2025
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/19/2025
Liquidia Co. stock logo
LQDA
Liquidia
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetMarket Perform ➝ Underperform$13.00
5/14/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$48.00
5/13/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
5/12/2025
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/12/2025
Liquidia Co. stock logo
LQDA
Liquidia
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$111.87M5.49N/AN/A$3.32 per share6.30
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$9.34M150.22N/AN/A$7.46 per share3.18
Liquidia Co. stock logo
LQDA
Liquidia
$14.14M85.70N/AN/A$0.73 per share19.42
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/A$3.84 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$163.62M-$4.85N/AN/AN/A-289.75%-287.94%-37.25%8/4/2025 (Estimated)
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$58.29M-$1.36N/AN/AN/A-463.91%-10.47%-9.86%8/6/2025 (Estimated)
Liquidia Co. stock logo
LQDA
Liquidia
-$78.50M-$1.58N/AN/AN/A-765.38%-163.21%-67.14%8/6/2025 (Estimated)
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)

Latest ANAB, LQDA, JANX, and MLYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$1.02-$0.79+$0.23-$0.79N/AN/A
5/8/2025Q1 2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A
5/8/2025Q1 2025
Liquidia Co. stock logo
LQDA
Liquidia
-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million
5/5/2025Q1 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million
3/19/2025Q4 2024
Liquidia Co. stock logo
LQDA
Liquidia
-$0.38-$0.46-$0.08-$0.46$4.60 million$2.92 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/AN/AN/AN/AN/A
Liquidia Co. stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
10.23
10.23
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/A
38.80
38.80
Liquidia Co. stock logo
LQDA
Liquidia
N/A
6.33
6.33
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/A
14.02
14.02

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
75.39%
Liquidia Co. stock logo
LQDA
Liquidia
64.54%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
84.46%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
33.50%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
8.10%
Liquidia Co. stock logo
LQDA
Liquidia
26.50%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
25.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10029.38 million20.17 millionOptionable
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3059.18 million37.05 millionOptionable
Liquidia Co. stock logo
LQDA
Liquidia
5085.49 million59.16 millionOptionable
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2865.18 million33.27 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$20.90 +0.77 (+3.83%)
Closing price 04:00 PM Eastern
Extended Trading
$20.92 +0.02 (+0.07%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Janux Therapeutics stock logo

Janux Therapeutics NASDAQ:JANX

$23.70 -0.54 (-2.23%)
Closing price 04:00 PM Eastern
Extended Trading
$23.84 +0.14 (+0.57%)
As of 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Liquidia stock logo

Liquidia NASDAQ:LQDA

$14.18 -1.42 (-9.10%)
Closing price 04:00 PM Eastern
Extended Trading
$14.22 +0.04 (+0.25%)
As of 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Mineralys Therapeutics stock logo

Mineralys Therapeutics NASDAQ:MLYS

$15.84 +0.11 (+0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$16.00 +0.16 (+1.01%)
As of 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.